PharmaShots | Incisive News in 3 Shots

Subscribe Now

hereditary angioedema

Takeda Publishes the Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks in the Journal Allergy

Takeda Publishes the Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks in...

August 6, 2021

Takeda Presents Results of Takhzyro (lanadelumab) in P-III HELP Study Open-Label Extension to Treat Hereditary Angioedema Attacks at EAACI 2021

Takeda Presents Results of Takhzyro (lanadelumab) in P-III HELP Study Open-Label Extension to Treat Hereditary Angioedema Attacks...

July 12, 2021

Orchard Collaborates with Pharming to Develop and Commercialize OTL-105 for Hereditary Angioedema

Orchard Collaborates with Pharming to Develop and Commercialize OTL-105 for Hereditary Angioedema

July 1, 2021

CSL Behring's Haegarda (C1 Esterase Inhibitor) Receives the US FDA's Approval for Pediatric Patients with Hereditary Angioedema

CSL Behring's Haegarda (C1 Esterase Inhibitor) Receives the US FDA's Approval for Pediatric Patients with Hereditary Angioedema

September 29, 2020

Shire's Takhzyro (lanadelumab-flyo) Receives FDA Approval Novel Hereditary Angioedema (HAE) in Age ≥12yrs

Shire's Takhzyro (lanadelumab-flyo) Receives FDA Approval Novel Hereditary Angioedema (HAE) in Age ≥12yrs

August 24, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us